Non-invasive detection and prognostic evaluation of cancer represents a formidable challenge. Studies of the entire metabolite composition of cells promise advances towards this objective for prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Sreekumar, A. et al. Nature 457, 910–914 (2009).
Griffin, J. L. & Shockcor, J. P. Nature Rev. Cancer 4, 551–561 (2004).
Spratlin, J. L., Serkova, N. J. & Eckhardt, S. G. Clin. Cancer Res. 15, 431–440 (2009).
Denkert, C. et al. Mol. Cancer 7, 72 (2008).
Ippolito, J. E. et al. Proc. Natl Acad. Sci. USA 102, 9901–9906 (2005).
Kind, T. et al. Anal. Biochem. 363, 185–195 (2007).
Varambally, S. et al. Nature 419, 624–629 (2002).
Martínez-Chantar, M. L. et al. Hepatology 47, 1191–1199 (2008).
Huang, Y.-C. et al. Clin. Cancer Res. 13, 1412–1420 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abate-Shen, C., Shen, M. The prostate-cancer metabolome. Nature 457, 799–800 (2009). https://doi.org/10.1038/457799a
Published:
Issue Date:
DOI: https://doi.org/10.1038/457799a
- Springer Nature Limited
This article is cited by
-
Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study
Tumor Biology (2016)
-
Paramagnetic Nanoparticles as a Platform for FRET-Based Sarcosine Picomolar Detection
Scientific Reports (2015)
-
The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer
Modern Pathology (2011)
-
Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study
BMC Cancer (2010)